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Single nucleotide polymorphisms (SNP) in various genes have been described to
be associated with susceptibility to autoimmune disease. In this study, myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients and controls were
genotyped for five immune gene SNPs in tyrosine phosphatase non-receptor type
22 (PTPN22, rs2476601), cytotoxic T-lymphocyte-associated protein 4 (CTLA4,
rs3087243), tumor necrosis factor (TNF, rs1800629 and rs1799724), and interferon
regulatory factor 5 (IRF5, rs3807306), which are among the most important risk
variants for autoimmune diseases. Analysis of 305 ME/CFS patients and 201 healthy
controls showed significant associations of the PTPN22 rs2476601 and CTLA4
rs3087243 autoimmunity-risk alleles with ME/CFS. The associations were only found
in ME/CFS patients, who reported an acute onset of disease with an infection
(PTPN22 rs2476601: OR 1.63, CI 1.04–2.55, p = 0.016; CTLA4 rs3087243: OR 1.53,
CI 1.17–2.03, p = 0.001), but not in ME/CFS patients without infection-triggered onset
(PTPN22 rs2476601: OR 1.09, CI 0.56–2.14, p = 0.398; CTLA4 rs3087243: OR 0.89,
CI 0.61–1.30, p = 0.268). This finding provides evidence that autoimmunity might play a
role in ME/CFS with an infection-triggered onset. Both genes play a key role in regulating
B and T cell activation.
Keywords: single nucleotide polymorphism (SNP), tyrosine phosphatase non-receptor type 22 (PTPN22), cytotoxic
T-lymphocyte-associated protein 4 (CTLA4), interferon regulatory factor 5 (IRF5), tumor necrosis factor (TNF),
myalgic encephalomyelitis (ME), chronic fatigue syndrome (CFS), autoimmunity
INTRODUCTION
With an estimated prevalence of 0.2–0.3%, myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS) is a frequent and severe chronic multisystemic disease. Patients suffer from persistent
exhaustion, cognitive dysfunctions, pain and flu-like symptoms, leading to a substantial reduction
of life quality (1). The underlying pathomechanism is not well-understood, but there is convincing
evidence that, at least in a subset of ME/CFS patients, autoimmunity contributes to disease
etiology (2, 3). Autoantibodies against various antigens, including neurotransmitter receptors, were
reported by several groups (3). Comorbidity with Hashimoto’s thyroiditis, fibromyalgia, postural
orthostatic tachycardia syndrome and a higher rate of autoimmune disease were reported for
ME/CFS patients and their families (2, 3).
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Enhanced immune activation and impairment of
immunological tolerance are considered as important risk
factors for autoimmunity. Autoimmune diseases are understood
as being multifactorial with involvement of genetic and
environmental factors. Disease onset is often triggered by
infections, and the link between infections and autoimmune
diseases is well-established (4). In recent years, genome-
wide association studies have revealed single nucleotide
polymorphisms (SNPs) in various genes to be associated with
the risk to develop autoimmune diseases. For most of these
SNPs, it was found that they confer gain- or loss-of-function in
enzymes or transcription factors that play a role in B and T cell
activation or cytokine production and cytokine signaling, which
are crucial mechanisms for the development of autoimmune
diseases (5–8). Among the most frequent variants associated
with multiple autoimmune diseases are the tyrosine phosphatase
non-receptor type 22 (PTPN22) SNP rs2476601, the cytotoxic
T-lymphocyte-associated protein 4 (CTLA4) SNP rs3087243, the
interferon regulatory factor 5 (IRF5) SNP rs3807306, and the
SNP rs1800629 in the gene tumor necrosis factor (TNF).
The PTPN22 SNP rs2476601 is one of the most important
susceptibility loci for autoimmunity and is associated with
myasthenia gravis (MG), type 1 diabetes (T1D), systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), and other
autoimmune disorders (9). This SNP was shown to play an
important role in T and B cell receptor signaling (5). The SNP
rs3087243 in CTLA4 is associated with several autoimmune
diseases, including SLE, RA, T1D, and Graves’ disease (8, 10–14).
The CTLA4 SNP has a protective effect, and the major allele G is
associated with autoimmunity. The G allele leads to an impaired
negative regulation of T cell activation. Within multiple sclerosis
(MS) patients, homozygous carriers of the G allele were shown to
express significantly lower CTLA4 protein levels in CD4+ T cells
(15). A SNP in IRF5, rs3807306, is another common autoimmune
susceptibility locus associated with RA, SLE, MS, and Crohn’s
disease (CD) and is linked to higher serum interferon-α (IFNα)
activity (measured by a reporter cell line) in SLE (7, 16–18).
The SNP rs1800629 in TNF is linked to various autoimmune
diseases, including CD, celiac disease, RA, and SLE (6, 19–21).
Another SNP in the TNF gene rs1799724 is associated with CD
and autoimmune hepatitis (AIH) (22, 23). Higher serum levels
of TNFα were shown in carriers of the TNF rs1799724 risk
genotype, while for the SNP rs1800629, data on an association
with elevated TNFα serum levels are inconclusive (6, 24).
A recently published systematic review of Wang et al.
summarizes the studies of genetic variants, which are associated
with ME/CFS (25). Several SNPs in cytokines and human
leukocyte antigen (HLA) associations were found in ME/CFS.
Two SNPs in TNF, rs1800629 (TNF-308) and rs1799724 (TNF-
857), were comparatively analyzed between a ME/CFS and
control cohort (26). A higher frequency of the TNF-857 T allele
was found in ME/CFS. Analysis of genetic variants in PTPN22,
CTLA4, and IRF5 were not described in ME/CFS so far.
In the present study, we comparatively analyzed the
prevalence of the five SNPs described above in ME/CFS patients
and healthy controls. ME/CFS onset is triggered by an infection
in approximately two thirds of patients (27). The link between
infections as a trigger of autoimmune diseases is well-established
(4). Therefore, we also studied a possible association of these
SNPs with an infection-triggered disease onset (ITO).
MATERIALS AND METHODS
Patients and Controls
ME/CFS patients were diagnosed at the outpatient clinic for
immunodeficiencies at the Institute for Medical Immunology at
the Charité-Universitätsmedizin Berlin, Germany. Diagnosis of
ME/CFS is based on Canadian Consensus Criteria (CCC) (28)
and exclusion of other medical or neurological diseases that may
cause fatigue. Autoimmune diseases were an exclusion criterion,
with the exception of Hashimoto’s thyroiditis, which is classified
as comorbidity in ME/CFS (1). Controls not suffering from
fatigue were recruited from staff. Characteristics of patients are
shown in Table 1. 232 of 305 patients stated that they had an
acute onset of illness with an infection (ITO). We retrospectively
collected the data of the types of infection from the patients
records and could classify most patients into the categories
“respiratory or gastrointestinal tract infection,” “primary EBV,” or
“history of viral or bacterial infection.” All patients and controls
were caucasian. The study was approved by the Ethics Committee
of Charité-Universitätsmedizin Berlin in accordance with the
TABLE 1 | Cohort characteristics.
ME/CFS
All w/ ITO w/o ITO
n = 305 n = 232 n = 73






30 (10–70) 30 (10–70) 38 (10–70)
Elevated TPO
antibody* >34 kU/l
8% (n = 158) 6% (n = 120) 13% (n = 38)
Elevated ANA >1:160 19% (n = 225) 20% (n = 163) 16% (n = 62)














ITO, infection triggered onset; w/, with; w/o, without; TPO, hyreoperoxidase antibodies;
ANA, Antinuclear antibodies; EBV, Epstein-Barr virus.
*not significant.
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1964 Declaration of Helsinki and its later amendments (EA4-
090-10). All patients and healthy controls recruited from staff
gave written informed consent.
DNA Extraction and Allelic Discrimination
PCR
We analyzed SNPs in genomic coding regions described as risk
factors for autoimmunity (Table 2) by allelic discrimination (AD)
polymerase chain reaction (PCR). Genomic DNA from patients
and healthy controls was obtained from whole blood samples
or peripheral blood mononuclear cells (PBMCs) using the
QIAmp DNA Blood Mini Kit (QIAGEN) and stored at −20◦C
in nuclease-free water until use. DNA was quantified using
NanoDropTM spectrophotometer. Genotyping of all five SNPs
(PTPN22 rs2476601, ID: C__16021387_20; CTLA4 rs3087243,
ID: C___3296043_10; TNF rs1800629, ID: C___7514879_10;
TNF rs1799724, ID: C__11918223_10; and IRF5 rs3807306, ID:
C___2691231_10) was performed using pre-designed TaqMan
allelic discrimination assay probes (Thermo Fisher). The
10µl PCR reactions contained 2 µl of template DNA (5 ng/µl),
0.5 µl of the SNP genotyping Assay Mix, 5 µl of TaqMan
Universal Mastermix II no UNG (Applied Biosystems), and 2 µl
sterile distilled water. PCR run was performed in a 7500 Fast &
7500 Real-Time PCR System (Applied Biosystems). Background
fluorescence was recorded performing a pre-read run for 1min
at 60◦C. Amplification was achieved through activation of
DNA polymerase for 10min at 95◦C, following 40 cycles of
melting for 15 s at 92◦C and annealing/extension for 1min at
60◦C. Afterwards, background fluorescence was automatically




rs2476601 A>G PTPN22 RA, SLE, T1D,
GD, MG (9)
Modulation of T
and B cell receptor
signaling (29)
rs3087243 G>A CTLA4 RA (11), SLE (12),
T1D (13)
Negative
regulation of T cell
activation
impaired (14)











rs3807306 G>T IRF5 RA (16), SLE (17),
MS (7), CD (18)
High serum IFNα
activity (17)
PTPN22, tyrosine-protein phosphatase non-receptor type 22; CTLA4, cytotoxic T-
lymphocyte-associated protein 4; TNF, tumor necrosis factor; IRF5, interferon regulatory
factor 5; AIH, autoimmune hepatitis; CD, Crohn‘s disease; GD, Grave‘s disease; MG,
Myasthenia Gravis; MS, Multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; T1D, Type 1 diabetes; UC, Ulcerative colitis.
subtracted from the amplification results by running a post-
read for 1min at 60◦C. AD PCR results were visualized in a
cluster plot of allele X vs. allele Y to distinguish between homo-
and heterozygosity.
Assessment of Soluble Immune Marker
and Lymphocytes
Lymphocyte phenotyping by flow cytometry including CD3+,
CD4+, and CD8+ T cells and CD19+ B cells and serum protein
analysis including C reactive protein (CrP), complement proteins
C3 and C4, soluble IL-2 receptor (IL-2R), IgG, and TNFα in LPS-
stimulated whole blood cells was carried out by Labor Berlin,
Charité Vivantes GmbH, Berlin.
Statistical Analysis
Allele distribution was analyzed using the additive model in a
2 × 2 and genotype distribution using a 2 × 3 contingency table
and tested for significance by χ2-square test. One-tailed t-tests
were performed to test for increased frequency of the known
autoimmunity risk alleles in ME/CFS patients. Odds ratio (OR)
and 95% confidence interval (CI) were calculated from the same
contingency tables.
The Hardy-Weinberg equilibrium (HWE) was tested using a
2× 3 χ2 table comparing the expected and observed genotypes of
each SNP. No significant deviation from HWE was observed for
any of the studied SNPs in patients or controls. The five SNP loci
analyzed, reside on different chromosomes (PTPN22 rs2476601
on chr1, CTLA4 rs3087243 on chr2, TNF SNPs rs1799724 and
rs1800629 on chr6, and IRF5 rs3807306 on chr7) therefore, a
physical linkage can be excluded.
Analysis of association of serum proteins and immune cells
with onset type or PTPN22 rs2476601 and CTLA4 rs3087243
risk variants were analyzed using the two-tailed Mann–Whitney
U test.
Statistical tests were performed using GraphPad Prism
software (Version 6.00) or R (31). A p ≤ 0.05 was considered
statistically significant.
RESULTS
Analysis of Allelic and Genotype
Distribution
We analyzed a cohort of 305 ME/CFS patients and 201 healthy
controls for potential disease association of the PTPN22, CTLA4,
TNF, and IRF5 SNPs that were described to be risk loci for various
autoimmune diseases (Table 2 and Supplementary Table 1).
We found a significantly increased frequency of the
PTPN22 rs2476601 risk allele A, that confers susceptibility to
autoimmunity, in ME/CFS patients (allele frequency (AF) 12%,
odds ratio (OR) 1.50, p = 0.033) compared to healthy controls
(AF 8%, n= 201;Table 3).When subgrouping patients according
to the type of onset of disease, we observed the significant
association of the PTPN22 rs2476601 risk allele A only in patients
with ITO (AF 13%, OR 1.63, n = 232, p = 0.016), but not
in those without ITO (AF 9%), compared to healthy controls
(AF 8%).
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TABLE 3 | Allele frequencies and genotypes.
Gene SNP Cohorts
ME/CFS all n = 305
ME/CFS w/ ITO n =232
ME/CFS w/o ITO n = 73
controls n = 201
Genotype counts
Mi/Het/Ma
Risk allele freq. p-value control
vs. ME/CFS
OR (95% CI)
PTPN22 rs2476601 G>A ME/CFS all 2/68/235 0.12 0.033 1.50 (0.97–2.31)
ME/CFS w/ ITO 1/57/174 0.13 0.016 1.63 (1.04–2.55)
ME/CFS w/o ITO 1/11/61 0.09 0.398 1.09 (0.56–2.14)
Controls 2/29/170 0.08
CTLA4 rs3087243 G>A ME/CFS all 36/155/114 0.63 0.012 1.34 (1.04–1.73)
ME/CFS w/ ITO 23/112/97 0.66 0.001 1.53 (1.17–2.03)
ME/CFS w/o ITO 13/43/17 0.53 0.268 0.89 (0.61–1.30)
Controls 38/102/61 0.56
IRF5 rs3807306 G>T ME/CFS all 74/140/91 0.47 0.136 0.87 (0.67–1.17)
ME/CFS w/ ITO 63/102/67 0.49 0.318 0.94 (0.72–1.23)
ME/CFS w/o ITO 11/38/24 0.41 0.023 0.68 (0.46–0.99)
Controls 50/104/47 0.51
TNF rs1800629 G>A ME/CFS all 6/77/222 0.15 0.319 0.92 (0.65–1.31)
ME/CFS w/ ITO 5/56/171 0.14 0.275 0.89 (0.61–1.30)
ME/CFS w/o ITO 1/21/51 0.16 0.491 1.01 (0.60–1.70)
Controls 4/55/142 0.16
TNF rs1799724 C>T ME/CFS all 5/52/248 0.10 0.096 0.77 (0.52–1.14)
ME/CFS w/ ITO 5/41/186 0.11 0.204 0.84 (0.56–1.27)
ME/CFS w/o ITO 0/11/62 0.08 0.043 0.55 (0.28–1.10)
Controls 2/47/150 0.13
PTPN22, tyrosine-protein phosphatase non-receptor type 22; CTLA4, cytotoxic T-lymphocyte-associated protein 4; TNF, tumor necrosis factor; IRF5, interferon regulatory factor 5; Mi,
minor; Het, heterozygous; Ma, major; freq., frequency; ITO, infection triggered onset; w/, with; w/o, without; OR, odds ratio; CI, confidence interval. Bold values indicate statistically
significant p-values (p ≤ 0.05).
Equally, the frequency of the CTLA4 rs3087243 risk allele G
is significantly higher in ME/CFS patients (AF 63%, OR 1.34),
compared to healthy controls (AF 56%; Table 3). Again, we
observed a significant association of the CTLA4 rs3087243 risk
allele G only in patients with ITO (AF = 66%, OR = 1.53,
p = 0.001), but not in those wthout ITO (AF 53%) compared
to healthy controls (AF 56%).
Oppositely, the AF of the IRF5 rs3807306 risk allele T was
significantly lower in ME/CFS patients without ITO (AF 41%,
OR 0.68, p = 0.023), compared to healthy controls (AF 51%;
Table 3). No difference in the risk AF of the TNF rs1800629
SNP between patients and controls was observed, but the AF
of the TNF rs1799724 risk allele T again was significantly lower
in ME/CFS patients without ITO (AF 8%, OR 0.55, p = 0.043),
compared to healthy controls (AF 13%, Table 3). No associations
with IRF5 or TNF was found in patients with ITO.
Further, we analyzed the genotype distribution for CTLA4
rs3087243 and PTPN22 rs2476601 (Figure 1). We found
a significant difference between the ME/CFS patients with
an ITO, compared to healthy controls (CTLA4 rs3087243:
p = 0.0061, PTPN22 rs2476601: p = 0.026). ME/CFS
patients without ITO had a similar genotype distribution as
healthy controls.
Association of Infection-Triggered Onset
and PTPN22 and CTLA4 Variants With
Immune Markers
We comparatively analyzed numbers of CD3+, CD4+, and
CD8+ T cells and CD19+ B cells, CrP, complement proteins
C3 and C4, soluble IL-2R, IgG, and TNFα in ME/CFS
patients with and without ITO. Patients with ITO had lower
CD19+ B cell levels (p = 0.05) and a trend toward lower
C3 levels (Figure 2A and Supplementary Table 2). In patients
with both, the risk allele in PTPN22 rs2476601 (Figure 2B
and Supplementary Table 3) or the homozygous risk allele
for CTLA4 rs3087243 (Figure 2C and Supplementary Table 4),
C4 levels (p = 0.06 and 0.004, respectively) but not C3
levels were decreased, while there was no difference in B
cell numbers.
CrP concentrations were significantly higher in
ME/CFS patients without ITO (Figure 2A), and
without the risk alleles of PTPN22 rs2476601-A
(Figure 2B) and CTLA4 rs3087243-G (Figure 2C and
Supplementary Tables 2–4).
CD3+, CD4+, and CD8+ T cells and soluble IL-2R, TNFα,
and IgG concentrations did not differ between patient subgroups
and risk variants (Supplementary Tables 2–4).
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FIGURE 1 | Genotype distribution of CTLA4 and PTPN22 SNPs. Distribution of major (black), hetero (white), and minor (gray) genotypes of CTLA4 rs3087243 (A) and
PTPN22 rs2476601 (B) in ME/CFS patients with (n = 232) and without infection triggered onset (n = 73), and healthy controls (n = 201). The risk allele G in
rs3087243 and A in rs2476601 are underlined. Statistical analyses were performed using 2 × 3 contingency tables and χ2- test. A p ≤ 0.05 was considered as
statistically significant. HC, healthy control; w/ ITO, with infection-triggered onset; w/o ITO, without infection-triggered onset.
FIGURE 2 | Association of disease onset type (A), PTPN22 SNP (B), or CTLA4 SNP (C) in ME/CFS patients with immune marker. Median with range of C3 and C4
complement levels [mg/dl], CD19+ B cells [/nl], and CrP [mg/dl] is shown for the ME/CFS subgroups (A) with (w/) or without (w/o) infection-triggered onset (ITO). (B)
without or with PTPN22 rs2476601 risk allele A or (C) without or with CTLA4 rs3087243 risk allele G. Statistical analysis was performed using Mann–Whitney U test.
A p ≤ 0.05 was considered as statistically significant.
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DISCUSSION
In this study, we evaluated five important SNPs that are
associated with various autoimmune diseases in ME/CFS
patients. Patients selected are representative of ME/CFS cohorts
reported by other groups (with two-thirds of patients being
female and reporting an ITO and an average disease severity of
a Bell score of 30) (27). In accordance with this recent US study,
ME/CFS onset in our patients was triggered most frequently by
an acute respiratory infection or suspected viral infection (27).
Also, a primary EBV infection in adolescence is a well-known
trigger of ME/CFS and was reported in 19% of our patients. A
primary EBV infection in adulthood is known as a risk factor for
various autoimmune diseases (32).
We found a strong association of the autoimmunity risk alleles
in CTLA4 rs3087243-G and PTPN22 rs2476601-A with ITO
ME/CFS. Carrying the PTPN22 rs2476601 risk allele A increased
the odds 1.6-fold for developing infection-triggered ME/CFS.
Carriers of the risk allele G of CTLA4 rs3087243 had 1.5-
fold-higher odds of developing ITO ME/CFS. Accordingly, the
genotype distribution for both SNPs was significantly different
in ME/CFS patients with ITO compared to healthy controls
(Figure 1).
Both, the PTPN22 rs2476601 and CTLA4 rs3087243 SNPs
were shown to be associated with numerous autoimmune
diseases, including T1D, SLE, and RA (8–10, 33). PTPN22
encodes a lymphoid tyrosine phosphatase that acts as a strong
negative regulator of T cell activation. A study by Vang et al.
provides evidence that the autoimmune risk allele A of PTPN22
rs2476601 confers gain-of-function. This may lead to lower T
cell receptor signaling and the inability to delete autoreactive T
cells or diminished activity of Tregs (5). Further, the PTPN22
rs2476601 risk allele may contribute to the generation of
autoreactive B cells via disturbances in clonal deletion and
receptor editing thus leading to impaired central tolerance (29).
This is supported by the finding that the strongest associations
with this SNP are found in autoimmune diseases in which
autoreactive T cells and autoantibodies have a major role in
the pathogenesis of the disease (29). In contrast, autoimmune
diseases in which Th17 cells play an important role, and those
of mucosal sites, tend to have no association with PTPN22 (29).
CTLA4 is expressed on CD4+ and CD8+ T cells upon
activation and has a crucial role as negative T cell regulator to
switch-off activated T cells (34). The risk allele G of rs3087243
leads to reduced levels of soluble CTLA4mRNA, which results in
enhanced T cell activity (10, 15, 33).
Similar to our findings, both the PTPN22 rs2476601
and CTLA4 rs3087243 risk variants were shown to be
susceptibility loci for autoimmune diseases including anti-
neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
(AAV) and autoimmune polyglandular autoimmunity (35, 36).
To our knowledge, the frequency of these SNPs has not been
studied in other ME/CFS patients yet.
We further correlated our SNP data with immune markers.
In patients with both the risk allele in PTPN22 rs2476601 or the
homozygous risk alleles for CTLA4 rs3087243, C4 but not C3
levels were decreased. An association of these risk variants with
C4 levels is not described in the literature. Low C4 levels are,
however, frequent in SLE (37), a disease which is associated with
both the risk allele in PTPN22 and CTLA4.
When comparing patient subgroups, only those with ITO
had diminished CD19+ B cells. B cell lymphocytopenia is a
frequent finding in SLE and RA and provides further evidence
for an autoimmune mechanism in ME/CFS patients with ITO
(38, 39). In contrast, levels of CrP were significantly higher in
ME/CFS patients without ITO and in those without the risk
alleles. This may suggest that, within the subgroup of ME/CFS
patients without ITO, there is a tendency to a more pro-
inflammatory response similar to patients with cancer-related
fatigue (40).
For the IRF5 rs3807306 risk allele T we observed a significantly
lower AF inME/CFS patients without ITO compared to controls.
This finding is unexpected and needs to be confirmed. We could
not detect a difference in the frequency of the TNF rs1800629
AF between ME/CFS patients and healthy controls, but we
again found a significantly lower AF of the TNF rs1799724
in ME/CFS patients without ITO compared to controls. This
finding is in contrast to the previous study by Carlo-Stella et al.,
analyzing 80 ME/CFS patients, which found a higher frequency
of the TNF-857 rs1799724 risk allele (26). We have no obvious
explanation for this difference. The patient cohort in the 2006
study was diagnosed according to Fukuda criteria, which are
less strict than the CCC criteria used in our study. Interestingly,
these SNPs are associated with enhanced serum levels of TNFα
and IFNα and also with autoimmune diseases of mucosal sites
(19, 41). It is tempting to speculate that patients, who can
produce higher levels of TNFα and IFNα, have a more effective
mucosal immunity and are therefore less prone to develop
ME/CFS. This is in line with our previous observation, that
a deficiency of the complement factor mannose binding lectin
(MBL), which results in susceptibility to infections, is associated
with ME/CFS (42).
There are other variants of immune or immune-related genes
described in ME/CFS as recently summarized (25). Several
SNPs in HLA class II region were found to be associated with
ME/CFS (43, 44). This association is another evidence for an
autoimmune pathomechanism, as the link between certain HLA
alleles and autoimmunity is well-established (45). Moreover,
there are studies showing an association with several SNPs in
the glucocorticoid receptor gene Nuclear Receptor Subfamily
3 Group C Member 1 (NR3C1). This receptor plays a role
in the regulation of the inflammatory response by affecting
the hypothalamic–pituitary–adrenal (HPA) axis activity trough
cortisol release (30, 46). For ME/CFS, a deregulated HPA axis
has been reported (47). In a similar manner, SNP variants
in the catechol-O-methyltransferase (COMT) gene and the ß2
adrenergic receptor described in ME/CFS may modulate the
immune response (48). Further studies found associations with
SNPs not related to the immune system, like variants associated
with muscle metabolism (49) and serotonergic system (50).
In conclusion, our study shows that the PTPN22 rs2476601
and CTLA4 rs3087243 autoimmunity risk variants are more
frequent in patients with ITO ME/CFS. This finding provides
further evidence that there is a genetic predisposition for
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ME/CFS. The associations with PTPN22 and CTLA4 SNPs point
to a role of autoreactive T and B cells in the pathomechanism
of ME/CFS. In contrast, the lack of association of CTLA4
and PTPN22 SNPs and the lower frequencies of IRF5 and
TNF risk variants in ME/CFS patients without ITO suggest
that the pathomechanism is distinct. These associations need
to be confirmed in other ME/CFS patient cohorts. Our
findings prompt us to intensify research into autoimmune
mechanisms and perform clinical studies with drugs targeting
autoreactive B cells.
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